Erratum: SPARC overexpression inhibits cell proliferation in neuroblastoma and is partly mediated by tumor suppressor protein PTEN and AKT (PLoS ONE (2012) 7:5 (e36093) DOI: 10.1371/journal.pone.0036093);SPARC overexpression inhibits cell proliferation in neuroblastoma and is partly mediated by tumor suppressor protein PTEN and AKT

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Bhoopathi, Praveen ^a   Gorantla, Bharathi ^a   Sailaja, G S ^a   Gondi, Christopher S ^a   Gujrati, Meena ^a   Klopfenstein, Jeffrey D ^a   Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEONECTIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLASMID VECTOR; PROTEIN KINASE B; SMALL INTERFERING RNA; PTEN PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE FUNCTION; GENE INTERACTION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; RADIOSENSITIVITY; GENETICS; HUMAN; METABOLISM; NEUROBLASTOMA; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; NEUROBLASTOMA; OSTEONECTIN; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE;

EID: 84860477076     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0228246     Document Type: Erratum

References (71)

1. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, et al. (2002) Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 62: 6462-6466.
2. Kurschat P, Mauch C, (2000) Mechanisms of metastasis. Clin Exp Dermatol 25: 482-489.
3. Poste G, Fidler IJ, (1980) The pathogenesis of cancer metastasis. Nature 283: 139-146.
4. Discher DE, Janmey P, Wang YL, (2005) Tissue cells feel and respond to the stiffness of their substrate. Science 310: 1139-1143.
5. Janmey PA, Winer JP, Murray ME, Wen Q, (2009) The hard life of soft cells. Cell Motil Cytoskeleton 66: 597-605.
6. Yeung T, Georges PC, Flanagan LA, Marg B, Ortiz M, et al. (2005) Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion. Cell Motil Cytoskeleton 60: 24-34.
7. Chlenski A, Cohn SL, (2010) Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol 21: 55-65.
8. Yan Q, Sage EH, (1999) SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 47: 1495-1506.
9. Tai IT, Tang MJ, (2008) SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat 11: 231-246.
10. Clark CJ, Sage EH, (2008) A prototypic matricellular protein in the tumor microenvironment-where there's SPARC, there's fire. J Cell Biochem 104: 721-732.
11. Podhajcer OL, Benedetti L, Girotti MR, Prada F, Salvatierra E, et al. (2008) The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 27: 523-537.
12. Bhoopathi P, Chetty C, Gujrati M, Dinh DH, Rao JS, et al. (2010) Cathepsin B facilitates autophagy mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells. Cell Death Differ 17: 1529-1539.
13. Nie J, Sage EH, (2009) SPARC functions as an inhibitor of adipogenesis. J Cell Commun Signal 3: 247-254.
14. Bhoopathi P, Chetty C, Dontula R, Gujrati M, Dinh DH, et al. (2011) SPARC Stimulates Neuronal Differentiation of Medulloblastoma Cells via the Notch1/STAT3 Pathway. Cancer Res 71: 4908-4919.
15. Dong JT, Li CL, Sipe TW, Frierson HF Jr, (2001) Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin Cancer Res 7: 304-308.
16. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
17. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362.
18. Stiles B, Gilman V, Khanzenzon N, Lesche R, Li A, et al. (2002) Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol Cell Biol 22: 3842-3851.
19. Weng L, Brown J, Eng C, (2001) PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and-independent pathways. Hum Mol Genet 10: 237-242.
20. Weng LP, Brown JL, Eng C, (2001) PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 10: 599-604.
21. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, et al. (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321.
22. Datta SR, Dudek H, Tao X, Masters S, Fu H, et al. (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241.
23. Vander Heiden MG, Thompson CB, (1999) Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol 1: E209-E216.
24. Tai IT, Dai M, Owen DA, Chen LB, (2005) Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 115: 1492-1502.
25. Iliakis G, Wang Y, Guan J, Wang H, (2003) DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 22: 5834-5847.
26. Teyssier F, Bay JO, Dionet C, Verrelle P, (1999) [Cell cycle regulation after exposure to ionizing radiation]. Bull Cancer 86: 345-357.
27. Yan Y, Cao PT, Greer PM, Nagengast ES, Kolb RH, et al. (2010) Protein phosphatase 2A has an essential role in the activation of gamma-irradiation-induced G2/M checkpoint response. Oncogene 29: 4317-4329.
28. Kastan MB, Bartek J, (2004) Cell-cycle checkpoints and cancer. Nature 432: 316-323.
29. Shiloh Y, (1997) Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. Annu Rev Genet 31: 635-662.
30. Jorgensen TJ, (2009) Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther 8: 665-670.
31. Zhan M, Han ZC, (2004) Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol 19: 915-923.
32. Manning BD, Cantley LC, (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
33. Tonic I, Yu WN, Park Y, Chen CC, Hay N, (2010) Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci. J Biol Chem 285: 23790-23798.
34. Francki A, McClure TD, Brekken RA, Motamed K, Murri C, et al. (2004) SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem 91: 915-925.
35. Li L, Feng Z, Porter AG, (2004) JNK-dependent phosphorylation of c-Jun on serine 63 mediates nitric oxide-induced apoptosis of neuroblastoma cells. J Biol Chem 279: 4058-4065.
36. Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, et al. (2007) Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 37: 389-396.
37. Thomas SL, Alam R, Lemke N, Schultz LR, Gutierrez JA, et al. (2010) PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling. Neuro Oncol 12: 941-955.
38. Granville CA, Memmott RM, Gills JJ, Dennis PA, (2006) Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 12: 679-689.
39. Dhanesuan N, Sharp JA, Blick T, Price JT, Thompson EW, (2002) Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res Treat 75: 73-85.
40. Liu H, Zhang H, Jiang X, Ma Y, Xu Y, et al. (2011) Knockdown of secreted protein acidic and rich in cysteine (SPARC) expression diminishes radiosensitivity of glioma cells. Cancer Biother Radiopharm 26: 705-715.
41. Sage H, Tupper J, Bramson R, (1986) Endothelial cell injury in vitro is associated with increased secretion of an Mr 43,000 glycoprotein ligand. J Cell Physiol 127: 373-387.
42. Briggs J, Chamboredon S, Castellazzi M, Kerry JA, Bos TJ, (2002) Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 21: 7077-7091.
43. Mettouchi A, Cabon F, Montreau N, Vernier P, Mercier G, et al. (1994) SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J 13: 5668-5678.
44. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, et al. (2001) SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159: 609-622.
45. Tang MJ, Tai IT, (2007) A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J Biol Chem 282: 34457-34467.
46. Perry ME, (2004) Mdm2 in the response to radiation. Mol Cancer Res 2: 9-19.
47. Bazan NG, (2006) The onset of brain injury and neurodegeneration triggers the synthesis of docosanoid neuroprotective signaling. Cell Mol Neurobiol 26: 901-913.
48. Yin XY, Grove L, Datta NS, Katula K, Long MW, et al. (2001) Inverse regulation of cyclin B1 by c-Myc and p53 and induction of tetraploidy by cyclin B1 overexpression. Cancer Res 61: 6487-6493.
49. Zhang W, Liu HT, (2002) MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12: 9-18.
50. Brognard J, Clark AS, Ni Y, Dennis PA, (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997.
51. Huang WC, Hung MC, (2009) Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 108: 180-194.
52. Cantley LC, Neel BG, (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240-4245.
53. Hollander MC, Blumenthal GM, Dennis PA, (2011) PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 11: 289-301.
54. Petersen S, Rudolf J, Bockmuhl U, Gellert K, Wolf G, et al. (1998) Distinct regions of allelic imbalance on chromosome 10q22-q26 in squamous cell carcinomas of the lung. Oncogene 17: 449-454.
55. Yokomizo A, Tindall DJ, Drabkin H, Gemmill R, Franklin W, et al. (1998) PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 17: 475-479.
56. Kupprion C, Motamed K, Sage EH, (1998) SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 273: 29635-29640.
57. Motamed K, Blake DJ, Angello JC, Allen BL, Rapraeger AC, et al. (2003) Fibroblast growth factor receptor-1 mediates the inhibition of endothelial cell proliferation and the promotion of skeletal myoblast differentiation by SPARC: a role for protein kinase A. J Cell Biochem 90: 408-423.
58. Motamed K, Funk SE, Koyama H, Ross R, Raines EW, et al. (2002) Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors. J Cell Biochem 84: 759-771.
59. Francki A, Motamed K, McClure TD, Kaya M, Murri C, et al. (2003) SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF-dependent signaling. J Cell Biochem 88: 802-811.
60. Bradshaw AD, Francki A, Motamed K, Howe C, Sage EH, (1999) Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Mol Biol Cell 10: 1569-1579.
61. Schiemann BJ, Neil JR, Schiemann WP, (2003) SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell 14: 3977-3988.
62. Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, et al. (2002) SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res 62: 7357-7363.
63. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, et al. (2003) Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 111: 487-495.
64. Puolakkainen PA, Brekken RA, Muneer S, Sage EH, (2004) Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2: 215-224.
65. Said N, Motamed K, (2005) Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 167: 1739-1752.
66. Chetty C, Bhoopathi P, Lakka SS, Rao JS, (2007) MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line. Oncogene 26: 7675-7683.
67. Bhoopathi P, Chetty C, Kunigal S, Vanamala SK, Rao JS, et al. (2008) Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB. J Biol Chem 283: 1545-1552.
68. Chetty C, Lakka SS, Bhoopathi P, Kunigal S, Geiss R, et al. (2008) Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer. Cancer Res 68: 4736-4745.
69. Healy E, Dempsey M, Lally C, Ryan MP, (1998) Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int 54: 1955-1966.
70. Chetty C, Bhoopathi P, Rao JS, Lakka SS, (2009) Inhibition of matrix metalloproteinase-2 enhances radiosensitivity by abrogating radiation-induced FoxM1-mediated G2/M arrest in A549 lung cancer cells. Int J Cancer 124: 2468-2477.
71. Tivnan A, Tracey L, Buckley PG, Alcock LC, Davidoff AM, et al. (2011) MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer 11: 33.